logo
Breast Milk Bank Helps Babies Thrive In Nepal

Breast Milk Bank Helps Babies Thrive In Nepal

Forbes07-06-2025
Hundreds of newborns receive the nourishment they need to survive and thrive through a program in Kathmandu supported by UNICEF, the government of Nepal and other partners. But plans to expand the services and reach more babies in need are on hold due to funding cuts.
New mother Sarita Khatri Tamang rests with her newborn baby in the Kangaroo Mother Care ward at the UNICEF-supported Paropakar Maternity and Women's Hospital in Kathmandu.
© UNICEF/UNI792286/Upadhayay
New mother Sarita Khatri Tamang holds her baby close as she lies in a bed recovering from a C-section delivery at Paropakar Maternity and Women's Hospital in Kathmandu.
She has been unable to breastfeed, but her baby is not missing out on the breast milk needed for optimal infant nutrition. Thanks to the hospital's Amrit Kosh — Nepal's first human milk bank — she is able to receive breast milk donated by other mothers.
"At a time when I could barely stand up because I was in so much pain," Tamang says, "it was such a big support for me."
The milk bank is part of a comprehensive lactation management center established in 2022 by the government of Nepal, with support from the European Union and UNICEF. The center ensures proper nourishment for newborns in critical condition, including many born prematurely. Around 500 babies are supported every month with donated breast milk — the next best thing to a mother's own milk.
Plans to open or expand similar lactation management units in hospitals across Nepal, particularly in facilities serving large numbers of at-risk newborns, have been put on hold due as recent funding cuts have affected UNICEF's ability to support these initiatives. Funding cuts have also disrupted other key UNICEF-supported services including breastfeeding support and counseling.
"The demand is still much higher than what the bank can currently supply on a daily basis," says Dr. Kalpana Upadhyaya Subedi, Chief Consultant Pediatrician and head of the Department of Neonatology at Paropakar. 'Expanding such facilities across the country would ensure that more mothers and babies receive the support they need, reducing neonatal mortality and promoting healthier outcomes for future generations."
Breastfeeding is the best form of nutrition for babies, especially for the first six months of life. But breast milk is more than a meal. It also plays a critical role in protecting vulnerable infants from infections and malnutrition.
On May 2, 2025, Dr. Smriti Poudel counsels new mother Sarita Khatri Tamang at the Paropakar Maternity and Women's Hospital in Kathmandu, where UNICEF supports Nepal's first Human Milk Bank. Expansion plans are on hold due to funding cuts.
© UNICEF/UNI792463/Rabik Upadha
Nepal faces significant challenges in early childhood nutrition. One in 4 children under age 5 is stunted, and 8 percent are wasted, with limited access to treatment, according to UNICEF. Nearly half of all infants are not exclusively breastfed, and over 1 million children suffer from anemia.
'It makes me happy to think that because of me, lives were saved.'
Sushila Nagarkoti is one of the mothers who has donated to the Kathmandu milk bank. "The nurse told me that I was producing a lot of milk and asked if I wanted to donate some; I said okay, since I had more than enough milk for my own child," Nagarkoti says. "It makes me happy to think that because of me, lives were saved."
Learn more about UNICEF programs in Asia
Your contribution to UNICEF is more important than ever. Please donate.
Right now, the lives of the most vulnerable children hang in the balance as conflicts and crises jeopardize the care and protection that they deserve. Dependable, uninterrupted and effective foreign aid is critical to the well-being of millions of children. Please contact your members of Congress and urge them to support ongoing U.S. investments in foreign assistance.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sanctions, on Rise, Are as Deadly as Armed Conflict, Study Says
Sanctions, on Rise, Are as Deadly as Armed Conflict, Study Says

Bloomberg

timean hour ago

  • Bloomberg

Sanctions, on Rise, Are as Deadly as Armed Conflict, Study Says

Sanctions can cause as many fatalities as armed conflict, with unilateral penalties being associated with more than half a million deaths per year, according to a new analysis. Unilateral and economic sanctions imposed by the US and the European Union lead to a substantial increase in mortality that disproportionately hurts children younger than five years old, the study published in the Lancet Global Health journal found. Sanctions can hobble public health provision and keep humanitarian organizations from operating effectively, weighing on the death toll.

Study: Lost weight rebounds quickly after stopping weight-loss jabs
Study: Lost weight rebounds quickly after stopping weight-loss jabs

Yahoo

time4 hours ago

  • Yahoo

Study: Lost weight rebounds quickly after stopping weight-loss jabs

Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Generate Key Takeaways Doctors around the world have been hailing "miracle" medications that make weight loss far easier, but new research suggests that after a person stops taking certain drugs, the weight tends to increase again rather quickly. People who received the medication lost significant weight during the therapy, and this even continued to a small extent for a few weeks after stopping the medication, according to a research team led by Han Wu and Wenjia Yang from Peking University People's Hospital. However, from the eighth week after the end of therapy, researchers said there was a marked weight gain that persisted for many weeks. The extent of weight gain varies depending on the medication and lifestyle changes, according to the study, but there is a clear trend towards weight gain after stopping the medication. This confirms existing findings, according to Stephan Martin, chief physician for diabetology and director of the West German Diabetes and Health Centre at the Association of Catholic Clinics in Düsseldorf, Germany. He said that some manufacturers of the medications had also demonstrated this themselves through randomized studies. Test subjects were given the active substances for 10 weeks, after which some were switched to a placebo. This group "then continuously regained weight," Martin reported. In the current study, the researchers from Beijing also referred to an investigation in which people who had completed a 36-week treatment with the active substance tirzepatide (GLP-1-RA) regained about half of the weight they had previously lost within a year of switching to a placebo. The newly published meta-analysis summarised the results of 11 independent studies from around the world, including those on the drug orlistat, the combinations naltrexone/bupropion and phentermine/topiramate, as well as the group of GLP-1 receptor agonists. The data came from a total of 1,574 people in treatment groups and 893 in control groups. GLP-1 receptor agonists (GLP-1-RA) are included in popular medications such as Wegovy and Ozempic. In some countries, they are approved for type 2 diabetes and some cases of obesity, and they are known as lifestyle drugs for achieving a slim figure. These active substances, which are injected regularly, primarily prolong the time food stays in the digestive tract, thereby increasing the feeling of satiety. Side effects include gastrointestinal complaints. One aspect of the study stands out: Those who initially experienced significant weight loss during therapy tended to regain more weight afterwards, even if they participated in programmes to change their lifestyle, such as eating and exercise habits. "This does not surprise me," says Anja Hilbert, professor of behavioural medicine at Germany's Leipzig University Hospital. Similar experiences are seen, for example, in people who follow a very low-calorie diet — they also tend to regain more weight after the diet ends than those who undergo moderate calorie limits. However, the expert noted that there were only a few participants for this aspect of the study. "The results of the study actually suggest that long-term, perhaps even lifelong use of the medication may be necessary to stabilise weight," Hilbert says. "It is a long-term therapy," diabetologist Martin emphasizes. Anyone who believes they can lose weight with this therapy and then everything will be fine is mistaken. "You need this therapy permanently." Some in the US health care system have raised concerns that many people may not be aware of this or may accept it. According to studies, two-thirds of people treated for obesity, most of whom pay for the treatment themselves, stopped using the medication within a year. "We don't know why: Maybe it becomes too expensive, maybe they have lost enough weight and believe it will now stay off," says Martin, who advocates for more overweight prevention rather than treating the consequences.

AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial
AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial

Yahoo

time10 hours ago

  • Yahoo

AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial

AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS) for those with first-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). According to the final analysis of the randomised Phase III trial, FLAURA2, it demonstrated a consistent survival benefit, echoing interim OS outcomes and building upon the earlier reported longest median progression-free survival (PFS) data for this setting. The combo showed OS improvements in the open-label, global, multi-centre trial when compared against Tagrisso as a single agent for this patient group. Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen. The chemotherapy included pemetrexed at a dosage of 500mg/m² and either cisplatin at 75mg/m² or carboplatin (AUC5) administered every three weeks for a total of four cycles. After completing the cycles, the treatment continued with Tagrisso alongside maintenance doses of pemetrexed, also given every three weeks. A total of 557 subjects were enrolled in the trial in more than 150 centres across over 20 nations, including in Asia, Europe, South America, and the US. PFS is the primary endpoint of the trial. The combination therapy's safety profile remained manageable, aligning with known profiles of the individual medicines. According to the company, the trial recorded higher adverse event rates in the combination arm, attributed to expected chemotherapy-related effects. Discontinuation rates due to adverse events remained low. These findings are set to be presented at an upcoming medical meeting and will be communicated to global regulatory bodies. AstraZeneca oncology haematology R&D executive vice-president Susan Galbraith said: 'These exciting overall survival results add to the extensive evidence supporting Tagrisso as the backbone therapy in EGFR-mutated lung cancer, demonstrating that Tagrisso plus chemotherapy can significantly extend survival in the first-line advanced setting, in addition to prior trials showing survival benefits as monotherapy in both early stage and advanced disease.' More than 80 nations, including the European Union (EU), the US, Japan, and China, have currently approved Tagrisso + chemotherapy based on the FLAURA2 trial data. In 2023, AstraZeneca reported positive outcomes from the ADAURA Phase III trial of Tagrisso in the adjuvant treatment of individuals with Stage IB, II, IIIA EGFRm NSCLC. "AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store